Loading...

Rein Therapeutics Inc.

RNTX•NASDAQ
Healthcare
Medical - Pharmaceuticals
$1.46
$0.04(2.82%)

Rein Therapeutics Inc. (RNTX) Company Profile & Overview

Explore Rein Therapeutics Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Rein Therapeutics Inc. (RNTX) Company Profile & Overview

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

SectorHealthcare
IndustryMedical - Pharmaceuticals
CEOJames Brian Windsor

Contact Information

http://www.reintx.com
737 802 1989
12407 N. Mopac Expy., Austin, TX, 78758

Company Facts

11 Employees
IPO DateJun 29, 2017
CountryUS
Actively Trading

Frequently Asked Questions

;